Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007
curred clinical site start up costs for our three co-therapy trials in the U.K. and our Phase II sarcoma clinical trial in the U.S. During the nine month period ending September 30, 2006, we incurred direct patient costs in four ongoing clinical trials along with clinical site start up costs associated with our U.S. recurrent malignant glioma and U.K. Phase Ia combination REOLYSIN(R)/radiation therapy trials.
We expect our clinical trial expenses will continue to increase for the remainder of 2007 compared to 2006 as we continue patient enrollment and expand our clinical trial program to include other trial sites and other studies.
Pre-Clinical Trial Expenses and Research Collaborations
2007 2006
$ $
-------------------------------------------------------------------------
Research collaboration expenses 694,315 634,199
Pre-clinical trial expenses 37,130 57,354
-------------------------------------------------------------------------
Pre-clinical trial expenses and
research collaborations 731,445 691,553
-------------------------------------------------------------------------
-------------------------------------------------------------------------
During the nine month period ending September 30, 2007, our research collaboration expenses were $694,315 compared to $634,199 for the nine month period ending September 30, 2006. Our research collaboration activity continues to focus on the interaction of the immune system and the reovirus, the use of the reovirus as a co-therapy with existing chemotherapeutics, the use of new RAS active viruses as potential therapeutics, and to investigate new uses of the reovirus as a therapeutic.
For the remainder of 2007, we still ex
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
(Date:5/22/2013)... May 22, 2013 Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... May 22, 2013 Cleveland BioLabs, Inc. (NASDAQ: CBLI) today ... Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of ... on May 30 at 1:30 p.m. Eastern Time. A live ... on the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Envera announced today that Michael McErlean has ... has an extensive background in cell production and served ... , Mike Matheny, President and Owner of ... join our team”. “Mike’s background is perfectly suited to ... and downstream processing equipment”, added Matheny. “Mike’s hands on ...
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2... 4 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... vice president of research and development, is scheduled ... Biotechnology & Medical Technology,Conference on June 12 at ... at the,New York Palace Hotel in New York ...
... $90.7 million, up 18% from the prior year,s second ... quarter, - Earnings per share of $0.28, an increase of approximately 87% over last ... quarter,- Operating cash flow of $23.6 million (Year-to-date operating cash flow of ... $38.8 million),- Launch of eight new food and beverage and four new nutritional supplement ...
... Collegiate Inventors and Innovators Alliance (NCIIA) presents, ... discoveries for, nerve injuries, premature babies ... Mass., June 4 Today the NCIIA presented ... work in the field. The top winners in ...
Cached Biology Technology:Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference 2Martek Announces Second Quarter 2008 Financial Results 2Martek Announces Second Quarter 2008 Financial Results 3Martek Announces Second Quarter 2008 Financial Results 4Martek Announces Second Quarter 2008 Financial Results 5Martek Announces Second Quarter 2008 Financial Results 6Martek Announces Second Quarter 2008 Financial Results 7Martek Announces Second Quarter 2008 Financial Results 8Martek Announces Second Quarter 2008 Financial Results 9Martek Announces Second Quarter 2008 Financial Results 10Martek Announces Second Quarter 2008 Financial Results 11Martek Announces Second Quarter 2008 Financial Results 12The NCIIA Recognizes Collegiate Biomedical Engineering Innovations 2The NCIIA Recognizes Collegiate Biomedical Engineering Innovations 3(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2... for the first time have shown the earliest stages ... of bones, teeth and sea shells. They ... a three-dimensional image of the nanoparticles that form the ... understanding of the formation of bones, teeth and shells. ...
... the most common vaginal infection in US women of childbearing ... the normal balance of bacteria in the vagina is disrupted ... BV puts a woman at increased risk for a variety ... in understanding how it can be prevented. Vitamin D may ...
... Va.The SNM Clinical Trials Network, an initiative designed ... through the integration of imaging biomarkers into multi-center ... supporter. SNM, the world,s largest medical and ... Clinical Trials Network in late 2008 to facilitate ...
Cached Biology News:Focus on the formation of bones, teeth and shells 2Vitamin D insufficiency linked to bacterial vaginosis in pregnant women 2SNM's clinical trials network gains added support from industry leader 2Form: Ready to use Applications: ELISA...
... Strips have hydrophobic plastic supports that ... contact with toxic/hazardous solutions. Paper segments on ... leach into solution. Complementary indicator charts provide ... graduated in 1pH units; In packs of ...
... Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs ... user-selectable wavelengths. ... ... ...
... System creates isogenic cell lines all ... the protein of interest. This homogeneous ... In this experiment the coding sequence ... into pcDNA5/FRT and transfected into Flp-In-293 ...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |